Citations

Showing 10 of 108162 citations.

Delivering Equitable Care to Underserved Neuro-oncology Populations
Porter, Alyx B. , Chukwueke, Ugonma , Mammoser, Aaron, Friday, Bret Edward Buckley, Hervey‐Jumper, Shawn L.

Mayo Clinic

American Society of Clinical Oncology Educational Book | April 8, 2021 | Volume: No volume available | Issue: 41 | Pages: 38-46

10.1200/edbk_320803 | PMID 33830829 Get It

It is widely recognized that subspecialized multidisciplinary care improves neuro-oncology outcomes. Optimizing patient outcomes relies on the expertise of the treating physicians, neuroradiology and neuropathology, and supportive services familiar with common neurologic syndromes that occur after brain tumor diagnosis and treatment. Despite an increasing number of providers, patient access to specialized multidisciplinary care and clinical trials remains limited. Barriers to equitable health care exist across the United States, with marginalized communities being impacted disproportionately. Such disparity causes increased morbidity and mortality for patients from backgrounds with various elements of diversity. Limited attention to this inequity has resulted in an incomplete understanding of the spectrum of experiences that patients with neuro-oncologic diseases encounter. Clinical trials represent the highest standard and quality of care in medicine, but inclusion of under-represented and underserved groups consistently lags behind counterpart participants from majority racial and ethnic groups. Through provider education as it pertains to issues from bias and health literacy to increasing clinical trial enrollment and offering opportunities through telemedicine, opportunities for improving access to high-quality neuro-oncologic care are explored.
Vaccination for Coronavirus Disease 2019 (COVID-19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches
Tsourdi, Elena , Yu, Elaine W , Beur, Suzanne M. Jan de , Drake, Matthew T. , Jan de Beur, Suzanne M , Drake, Matthew T

Mayo Clinic

Journal of Bone and Mineral Research | April 8, 2021 | Volume: 36 | Issue: 6 | Pages: 1042-1047

10.1002/jbmr.4304 | PMID 33831269 Get It

ABSTRACT The development of coronavirus disease 2019 (COVID-19) vaccines has proceeded at an unprecedented pace, with numerous trials conducted simultaneously across the world as a result of massive technological and financial resource expenditures. With multiple vaccines having now received regulatory approval, public health efforts to promote widespread vaccine dissemination are currently underway. There has been particular emphasis placed on vaccination of older populations, the age group in which COVID-19 infection has been most lethal. However, such widespread vaccination approaches have necessarily raised important questions related to potential interactions with underlying diseases and concomitant treatments among persons to be vaccinated. Osteoporosis is a chronic condition marked by reduced bone strength and an associated increased risk for fracture that generally requires sustained medical intervention(s). Osteoporosis is neither associated with a higher risk of COVID-19 infection nor by more pronounced disease severity following infection, such that individuals with osteoporosis need not be more highly prioritized for COVID-19 vaccination. Osteoporosis therapies do not interfere with the efficacy or side effect profiles of COVID-19 vaccines and should not be stopped or indefinitely delayed because of vaccination. Depending on the specific drug profile within an anti-osteoporosis medication category, minor adjustments to the timing of drug administration may be considered with respect to the patient's COVID-19 vaccination schedule. Herein we provide practical recommendations for the care of patients requiring treatment for osteoporosis in the setting of COVID-19 vaccination. © 2021 American Society for Bone and Mineral Research (ASBMR).
Protocadherin 7–Associated Membranous Nephropathy
Sethi, Sanjeev , Morelle, Johann , Charlesworth, M. Cristine , Gross, LouAnn, Negron, Vivian , Buob, David , Chaudhry, Sidharth, Jadoul, Michel , Morelle, Johann , Jadoul, Michel , Madden, Benjamin J. , Dêbiec, Hanna , Charlesworth, M. Cristine , Fervenza, Fernando C. , Ronco, Pierre Marie

Mayo Clinic

Journal of the American Society of Nephrology | April 8, 2021 | Volume: 32 | Issue: 5 | Pages: 1249-1261

10.1681/asn.2020081165 | PMID 33833079 Get It

Significance Statement Membranous nephropathy (MN) results from antibodies targeting an antigen in the glomerular basement membrane (GBM). The target antigens identified so far include PLA2R, THSD7A, NELL1, SEMA3B, and EXT1/EXT2. Using laser microdissection and mass spectrometry analysis, the authors identified a novel protein, protocadherin 7 (PCDH7), that is present in the GBM of a subset of patients with MN who are negative for all of the known antigens associated with MN. PCDH7 shows granular GBM staining and colocalizes with Ig in the GBM. Furthermore, antibodies to PCDH7 were detected in both the serum and kidney biopsy tissue from individuals with PCDH7-associated MN but not from controls. These findings suggest that PCDH7-associated MN defines a distinct type of MN. Background Membranous nephropathy (MN) results from deposition of antigen-antibody complexes along the glomerular basement membrane (GBM). PLA2R, THSD7A, NELL1, and SEMA3B account for 80%–90% of target antigens in MN. Methods We performed laser microdissection and mass spectrometry (MS/MS) in kidney biopsies from 135 individuals with PLA2R-negative MN, and used immunohistochemistry/immunofluorescence and confocal microscopy to confirm the MS/MS finding, detect additional cases, and localize the novel protein. We also performed MS/MS and immunohistochemistry on 116 controls and used immunofluorescence microscopy to screen biopsy samples from two validation cohorts. Western blot and elution studies were performed to detect antibodies in serum and biopsy tissue. Results MS/MS studies detected a unique protein, protocadherin 7 (PCDH7), in glomeruli of ten (5.7%) PLA2R-negative MN cases, which also were negative for PLA2R, THSD7A, EXT1/EXT2, NELL1, and SEMA3B. Spectral counts ranged from six to 24 (average 13.2 [SD 6.6]). MS/MS did not detect PCDH7 in controls (which included 28 PLA2R-positive cases). In all ten PCDH7-positive cases, immunohistochemistry showed bright granular staining along the GBM, which was absent in the remaining cases of PLA2R-negative MN and control cases. Four of 69 (5.8%) cases in the validation cohorts (all of which were negative for PLA2R, THSD7A, EXT1, NELL1, and SEMA3B) were PCDH7-positive MN. Kidney biopsy showed minimal complement deposition in 12 of the 14 PCDH7-associated cases. Confocal microscopy showed colocalization of PCDH7 and IgG along the GBM. Western blot analysis using sera from six patients showed antibodies to nonreduced PCDH7. Elution of IgG from frozen tissue of PCDH7-associated MN showed reactivity against PCDH7. Conclusions MN associated with the protocadherin PCDH7 appears to be a distinct, previously unidentified type of MN.
Relationship between symptoms during a gastric emptying study, daily symptoms and quality of life in patients with diabetes mellitus
Kuwelker, Saatchi, Prichard, David O. , Bailey, Kent R. , Bharucha, Adil E.

Mayo Clinic

Neurogastroenterology & Motility | April 8, 2021 | Volume: 33 | Issue: 12 | Pages: No page available

10.1111/nmo.14154 | PMID 33830588 Get It

AbstractAimsGastric emptying is of limited utility for predicting the severity of symptoms in patients with diabetes mellitus and gastrointestinal symptoms. We evaluated the extent to which symptoms recorded during a 13C‐spirulina‐based gastric emptying breath test (GEBT) or scintigraphy predicting the severity of daily symptoms in diabetes mellitus.MethodsGastric emptying, symptoms during a gastric emptying study, either scintigraphy (n = 38) or GEBT (n = 111), and daily gastrointestinal symptoms were evaluated in 149 patients with diabetes mellitus and variably severe gastrointestinal symptoms.Key ResultsGastric emptying was normal, delayed, and rapid in 37%, 52%, and 9% measured with the GEBT and 55%, 34%, and 11% of patients measured with scintigraphy; differences between GEBT and scintigraphy were not significant. Daily symptoms were moderately severe or more intense in 58% and 21% of patients undergoing scintigraphy and GEBT (P < 0.0001). Symptoms during the GEBT (46%) and emptying thalf (3%) explained 50% of the variance in daily symptoms in the GEBT group. In the scintigraphy group, symptoms explained 29% of this variance; the thalf was insignificant. Patients who reported that one or more symptoms were more severe than the others during the GE study were more likely (OR 3.98, 95% CI 2.16, 7.33) to report the same symptom(s) as being the most severe in the daily diary.ConclusionsSymptoms during a GEBT and to a lesser extent during scintigraphy, but not gastric emptying predict the severity of daily symptoms and may serve as a biomarker in patients with diabetes mellitus.
Faculty Opinions recommendation of Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Ansell, Stephen M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739749983.793583991 Get It

An Analysis of Medicare Reimbursement for Neurosurgeon Office Visits: 2010 Compared to 2018
Harrington, M., Pollock, Jordan R. , Haglin, Jack M. , Richter, Kent R. , Patel, Naresh P. , Harrington, Maya T, Pollock, Jordan Riley , Patel, Naresh P

Mayo Clinic

Neurosurgery | April 8, 2021 | Volume: 89 | Issue: 1 | Pages: E42-E48

10.1093/neuros/nyab131 | PMID 34000736 Get It

Abstract BACKGROUND Trends in Medicare billing and procedural reimbursement for outpatient office visits remain unclear within the field of neurosurgery. OBJECTIVE To analyze financial trends of neurosurgeon reimbursement for Medicare office visits in 2010 compared to 2018. METHODS The 2010 and 2018 physician/supplier files from the Centers for Medicare and Medicaid Services website were utilized. All payments submitted by neurosurgeons (provider ID 14) were included. Trends in office visit Current Procedural Terminology codes 99201 to 99205 and 99211 to 99215 were analyzed. RESULTS Neurosurgeons billed for 1 109 979 office visits (463 611 h) in 2010 and Medicare denied 63 704 payments (totaling $11 205 283). Neurosurgeons billed for 1 189 046 office visits (508 526 h) in 2018 and Medicare denied 57 048 payments (totaling $15 103 879). This is a 7.1% increase in total neurosurgery office visits billed to Medicare, 9.7% increase in total office hours, and 34.8% increase in the payment amounts denied over 8 yr. Furthermore, after adjusting for inflation, the average amount paid to physicians by Medicare decreased by 8.3% per office visit. Additionally, Medicare paid 36.1% of the total neurosurgeon submitted charge amount for all office visits in 2010 but paid only 27.8% in 2018 (−8.3%). CONCLUSION Neurosurgeons are performing more office visits and billing for more time with patients. Meanwhile, Medicare has been paying physicians less per office visit, denying higher amounts of payments and reimbursing a decreasing percentage of submitted charges for office visits. An understanding of these trends is necessary to ensure continued equity and quality access to neurosurgical care in the United States.
Autologous stem cell transplantation in the age of ANDROMEDA
Bal, Susan , Gertz, Morie A.

Mayo Clinic

British Journal of Haematology | April 8, 2021 | Volume: 193 | Issue: 5 | Pages: 865-866

10.1111/bjh.17445 | PMID 33829514 Get It

Genetic variants related to successful migraine prophylaxis with verapamil
Cutrer, F. Michael , Moyer, Ann M. , Atkinson, Elizabeth J. , Wang, Liguo , Tian, Shulan , Wu, Yanhong , Garza, Ivan , Robertson, Carrie E. , Huebert, Carey, Moore, Brenda E., Cutrer, Fred Michael , Huebert, Carey A, Wang, Liguo , Robertson, Carrie E , Klein, Christopher J.

Mayo Clinic

Molecular Genetics & Genomic Medicine | April 8, 2021 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/mgg3.1680 | PMID 33829662 Get It

AbstractBackgroundCurrently, there is no biologically based rationale for drug selection in migraine prophylactic treatment.MethodsTo investigate the genetic variation underlying treatment response to verapamil prophylaxis, we selected 225 patients from a longitudinally established, deeply phenotyped migraine database (N = 5983), and collected uninterrupted quantitated verapamil treatment response data and DNA for these 225 cases. We recorded the number of headache days in the four weeks preceding treatment with verapamil and for four weeks, following completion of a treatment period with verapamil lasting at least five weeks. Whole‐exome sequencing (WES) was applied to a discovery cohort consisting of 21 definitive responders and 14 definitive non‐responders, and the identified single nucleotide polymorphisms (SNPs) showing significant association were genotyped in a separate confirmation cohort (185 verapamil treated patients). Statistical analysis of the WES data from the discovery cohort identified 524 SNPs associated with verapamil responsiveness (p < 0.01); among them, 39 SNPs were validated in the confirmatory cohort (n = 185) which included the full range of response to verapamil from highly responsive to not responsive.ResultsFourteen SNPs were confirmed by both percentage and arithmetic statistical approaches. Pathway and protein network analysis implicated myo‐inositol biosynthetic and phospholipase‐C second messenger pathways in verapamil responsiveness, emphasizing the earlier pathogenic understanding of migraine. No association was found between genetic variation in verapamil metabolic enzymes and treatment response.ConclusionOur findings demonstrate that genetic analysis in well‐characterized subpopulations can yield important pharmacogenetic information pertaining to the mechanism of anti‐migraine prophylactic medications.
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)
Choueiri, Toni K. , Zakharia, Yousef , Pal, Sumanta K. , Kocsis, Judit , Pachynski, Russell K. , Poprach, Alexandr , Starr, Mark D. , Owzar, Kouros , deShazo, Mollie, Lara, Primo N. , Géczi, Lajos , Ho, Thai H. , Walsh, Meghara , Adams, Bonne J., Robertson, Liz, Darif, Mohamed, Theuer, Charles P. , Ho, Thai , Choueiri, Toni K , Pachynski, Russell K , Zakharia, Yousef , Nixon, Andrew B. , Liu, Yingmiao , Lyu, Jing, Agarwal, Neeraj

Mayo Clinic

The Oncologist | April 8, 2021 | Volume: 26 | Issue: 7 | Pages: 560-e1103

10.1002/onco.13777 | PMID 33829609 Get It

Abstract Lessons Learned Background Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors. This study evaluated an antiendoglin monoclonal antibody (carotuximab, TRC105) combined with axitinib in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC) who had progressed following one or more prior VEGF inhibitors. Methods TRAXAR was a multicenter, international randomized 1:1 (stratified by ECOG, 0 vs. 1), phase II study of carotuximab combined with axitinib versus axitinib alone in mccRCC patients who had progressed following one or more prior VEGF inhibitors. The primary endpoint was progression-free survival (PFS) assessed by independent central review (ICR) per RECIST 1.1 Results A total of 150 patients were randomized. The combination therapy resulted in shorter median PFS by RECIST 1.1 than axitinib monotherapy (6.7 vs. 11.4 months). The combination was tolerated similarly to axitinib monotherapy, and there were no treatment related deaths. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. Conclusion The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.
Endocannabinoid Response in Acute Ischemic Stroke
Buciuc, Marina , Conte, Gian Marco , Scharf, Eugene , Scharf, Eugene L , Buciuc, Marina , Conte, Gian Marco

Mayo Clinic

Stroke | April 8, 2021 | Volume: 52 | Issue: 5 | Pages: No page available

10.1161/strokeaha.121.034131 | PMID 33827241 Get It